Loading...

ROIV ROIVANT SCIENCES LTD Expansion Plans 8-K Filing

RVNT

RV

ROIVANT SCIENCES LTD

(ROIV)

2025 8-K

Investor Day Announcement

Quarterly Results

Positive Study Results

Shareholder Meeting Summary

Graves' Disease Update

Financial Statements

Leadership Changes

Management Change

Management Change

Financial Results

Financial Results

Merger Completion

Merger Agreement

Merger Announcement

Annual Meeting Results

New Pipeline Program

Graves Disease Update

Financial Results Announcement

Debt Renegotiation and Equi...

Earnings Reports

Financial Results Announcement

Sale of Telavant Holdings, ...

Acquisition of Telavant Hol...

Announcement of Clinical Tr...

Announcement of Study Results

Financial Results Announcement

Investment Offering

Annual General Meeting of S...

Redemption of Warrants

Redemption Fair Market Valu...

Financial Results Announcement

Resignation of Director

Redemption of Warrants

Financial Results Announcement

Positive Trial Results Anno...

Appointment of Director

Positive Trial Results Anno...

Resignation of Director

Financial Results Announcement

Underwriting Agreement

Financial Update

Interim Data Announcement

External Links:

On September 17, 2025, Roivant Sciences Ltd. reported positive results from its Phase 3 VALOR study of brepocitinib for dermatomyositis, along with a presentation available on their investor relations website.

AI Assistant

ROIVANT SCIENCES LTD

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.